DOCSLIB.ORG

Frontiers in Dermatology and Venereology - a Series of Theme Issues in Relation to the 100-Year Anniversary of Actadv

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ISSN 0001-5555 ActaDV Volume 100 2020 Theme issue ADVANCES IN DERMATOLOGY AND VENEREOLOGY A Non-profit International Journal for Interdisciplinary Skin Research, Clinical and Experimental Dermatology and Sexually Transmitted Diseases Frontiers in Dermatology and Venereology - A series of theme issues in relation to the 100-year anniversary of ActaDV Official Journal of - European Society for Dermatology and Psychiatry Affiliated with - The International Forum for the Study of Itch Immediate Open Access Acta Dermato-Venereologica www.medicaljournals.se/adv ACTA DERMATO-VENEREOLOGICA The journal was founded in 1920 by Professor Johan Almkvist. Since 1969 ownership has been vested in the Society for Publication of Acta Dermato-Venereologica, a non-profit organization. Since 2006 the journal is published online, independently without a commercial publisher. (For further information please see the journal’s website https://www. medicaljournals.se/acta) ActaDV is a journal for clinical and experimental research in the field of dermatology and venereology and publishes high- quality papers in English dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of review articles in special areas, as well as Correspondence to the Editor to stimulate debate. New books are also reviewed. The journal has rapid publication times. Editor-in-Chief: Olle Larkö, MD, PhD, Gothenburg Former Editors: Johan Almkvist 1920–1935 Deputy Editors: Sven Hellerström 1935–1969 Anette Bygum, MD, PhD, Odense Nils Thyresson 1969–1987 Magnus Lindberg, MD, PhD, Örebro Lennart Juhlin 1987–1999 Elisabet Nylander, MD, PhD, Umeå Anders Vahlquist 1999–2017 Kaisa Tasanen-Määttä, MD, PhD, Oulu Artur Schmidtchen 2018–2019 Section Editors: Tasuku Akiyama, Miami (Neurodermatology and Itch - Experimental) Annamari Ranki, Helsinki (Cutaneous lymphoma) Nicole Basset-Seguin, Paris (Skin cancer) Artur Schmidtchen, Lund (Wound healing and Innate immunity) Veronique Bataille, London (Melanoma, Naevi, Photobiology) Matthias Schmuth, Innsbruck (Genodermatoses and Keratinizing disorders, Josip Car, Singapore (Health Services Research and e-Health) Ichthyosis and Retinoids) Brigitte Dréno, Nantes (Acne and Rosacea) Lone Skov, Hellerup (Psoriasis) Regina Fölster-Holst, Kiel (Paediatric dermatology, Atopy and Parasitoses) Enikö Sonkoly, Stockholm (Psoriasis and related disorders) Jürg Hafner, Zürich (Skin cancer, Skin tumours, and Melanoma) Jacek Szepietowski, Wrocław (Psychodermatology) Jürgen Harder, Kiel (Cutaneous innate defense, Skin microbe interactions) Elke Weisshaar, Heidelberg (Itch and Neurodermatology) Roderick Hay, London (Cutaneous Infections) Margitta Worm, Berlin (Atopic dermatitis and Immunology) Kristian Kofoed, Copenhagen (STD and Microbiology) Claus Zachariae, Hellerup (Contact dermatitis, Acute dermatology) Veli-Matti Kähäri, Turku (Skin cancer) Magnus Ågren, Copenhagen (Wound healing & Extracellular matrix) Dennis Linder, Graz/Padua (Psychoderm., Dermato -epidemiology, e-Health) Advisory Board: Masashi Akiyama, Nagoya Rudolf Happle, Freiburg Lisa Naysmith, Edinburgh Mona Ståhle, Stockholm Wilma Bergman, Leiden Lars Iversen, Aarhus Jonathan Rees, Edinburgh Sonja Ständer, Münster Tilo Biedermann, Munich Peter van de Kerkhof, Nijmegen Jean Revuz, Paris Jouni Uitto, Philadelphia Magnus Bruze, Malmö Irene Leigh, Dundee Johannes Ring, Munich Shyam Verma, Vadodara Earl Carstens, Davis John McGrath, London Matthias Ringkamp, Baltimore Gil Yosipovitch, Miami Thomas Diepgen, Heidelberg Maja Mockenhaupt, Freiburg Inger Rosdahl, Linköping Giovanna Zambruno, Rome Charlotta Enerbäck, Linköping Dedee Murrell, Sydney Thomas Ruzicka, Munich Christos C. Zouboulis, Dessau Kilian Eyerich, Stockholm All correspondence concerning manuscripts, editorial matters and subscription should be addressed to: Acta Dermato-Venereologica S:t Johannesgatan 22, SE-753 12 Uppsala, Sweden Editorial Manager, Mrs Agneta Andersson Editorial Assistant: Ms Anna-Maria Andersson Please send an E-mail Please send an E-mail Information to authors: Acta Dermato-Venereologica publishes papers/reports on scientific investigations in the field of dermatology and venereology, as well as reviews. Case reports and good preliminary clinical trials or experimental investigations are usually published as Short Communications. However, if such papers are of great news value they could still be published as full articles. Special contributions such as extensive feature articles and proceedings may be published as supplements to the journal. For detailed instructions to authors see https://www.medicaljournals.se/acta/instructions-to-author. Publication information: Everything is Open Access and no subscription fee. For publication fees: see https://www.medicaljournals.se/acta/ instructions-to-author. Indexed in: See https://www.medicaljournals.se/acta/about/adv. 1 FOREWORD Acta Dermato-Venereologica – 100 years DV The celebrations comprice a symposium and a series of theme issues jointly called ”Frontiers in Dermatology cta and Venereology” A In 1920, Acta Dermato-Venereologica (ActaDV) was As part of the celebration of the journal’s 100 years founded in Stockholm by the Chairman of Dermatology birthday, ActaDV will organize a symposium ”Frontiers and Syphilidology at Karolinska Institutet, Professor in Dermatology and Venereology” with invited speakers Johan Almkvist. To begin with, it was a minor tri-lingual from Europe and the USA (see full program below), and journal (German, French, English) with contributions publish a series of connected theme issues with contri- mainly from Europe. Today, 100 years and 6 editors later, butions from the speakers and other invited key-opinion- the journal is an online, open access and peer-reviewed leaders around the world (see next page). It is hoped that publication, own by a non-profit society and produced these undertakings will help to spur the scientific interest enereologica entirely in-house without any dependency on a com- in Dermatology and Venereology. V mercial publisher. For an historic review see Vahlquist A. On behalf of the editorial board and as principal orga- ActaDV 100 years – An incomplete history1. Annually, nizer of the centenary celebrations, I wish to sincerely ActaDV releases 250–300 papers submitted from all thank all the authors who kindly accepted to contribute to ermato- around the world. The acceptance rate is around 50% the theme issues, the specially appointed theme editors, D and the impact factor 3.4–4.2 in recent years, i.e. among and the skilful work of the editorial office without which top 10 in the field. nothing of this had been possible. cta Uppsala in December 2019 A Anders Vahlquist 1Vahlquist A. ActaDV 100 years – An incomplete history. Forum for Nord Former Editor-in-Chief and current Chairman of the Derm Venereol 2020; 24 (in press). Society for Publication of Acta Dermato-Venereologica DV cta Acta Dermato-Venereologica will celebrate its 100-year anniversary with a symposium th A Date: 15 May 2020. Place: Swedish Society of Medicine, Stockholm, Sweden Frontiers in Dermatology and Venereology Programme: Chairperson: Olle Larkö 9.00–10.30 ”ActaDV 100 year; an historic perspective”, Anders Vahlquist ”Skin fragility and blistering diseases”, Leena Bruckner-Tuderman ”Is permanent cure for genodermatoses in sight”, Jouni Uitto 10.50–12.00 ”Psoriasis: News in pathogenesis and therapy”, Jonathan Barker ”Where are we with prevention of atopic dermatitis?”, Hywel Williams Chairperson: Anders Vahlquist 13.00–14.10 ”Melanoma: News in epidemiology and therapy”, Julia Newton-Bishop ”Itch; scratching the surface is not enough”, Gil Yosipovitch 14.30–16.00 ”Combatting skin infections: A priority not just in Africa”, Roderick Hay Angelika Stary Olle Larkö The registration for this symposium is open. For more information (https://medicaljournals.se/acta/Acta100Year. pdf) and registration form (https://medicaljournals.se/actadv100/registration.php). dvances in dermatology and venereology A This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta Journal Compilation © 2020 Acta Dermato-Venereologica. Frontiers in Dermatology and Venereology DV Centenary theme issues in Volume 100 of Acta Dermato-Venereologica An overview cta A Current issue Itch and pruritic disorders Theme editors: Elke Weisshaar, Tasuku Akiyama and Jacek Szepietowski • The Challenge of Basic Itch Research, E. Carstens, T. Follansbee, M.I. Carstens • Mechanisms and Management of Itch in Dry Skin, C. Sagita Moniaga, M. Tominaga, K. Takamori • Non-dermatological Challenges of Chronic Itch, A.E. Kremer, T. Mettang, E. Weisshaar • Itch and Psyche: Bilateral Associations, R. Reszke, J.C. Szepietowski • A New Generation of Treatments for Itch, E. Fowler, G. Yosipovitch enereologica • Challenges in Clinical Research and Care in Pruritus, M.P. Pereira, C. Zeidler, M. Storck, K. Agelopoulos, W.D. Philipp-Dormston, V A.G.S. Zink, S. Ständer ermato- Forthcoming issues D Psoriasis cta Theme editors: Lone Skov and Enikö Sonkoly A • Psoriasis and Genetics, N. Dand, S. Mahil, F. Capon, C.H. Smith, M.A. Simpson and J. Barker • The Woronoff Ring in Psoriasis and the Mechanisms of Postinflammatory Hypopigmentation, J. Prinz • Psoriasis and Treatment: Past, Present and Future Aspects C. Reid, C.E.M. Griffiths • Psoriasis and Co-morbidity, M. Amin, E.B. Lee, T-F. Tsai, J.J. Wu • Pustular Psoriasis: the Dawn of a New Era, H. Bachelez DV Blistering skin disorders Theme editor:
Recommended publications
  • Stanford Chem-H Presentation (PDF)

    Stanford Chem-H Presentation (PDF)

    KiNativ® In situ kinase profiling Stanford University ChEM-H confidential @KiNativPlatform Principle of the KiNativ platform • ATP (or ADP) acyl phosphate binds to, and covalently modifies Lysine residues in the active site • Thus, ATP acyl phosphate with a desthiobiotin tag can be used capture and quantitate kinases in a complex lysate Acyl phosphate Desthiobiotin tag ATP 2 ATP acyl phosphate probe covalently modifies kinase in the active site Lysine 2 Lysine 1 3 ATP acyl phosphate probe covalently modifies kinase in the active site Lysine 2 Lysine 1 4 Samples trypsinized, probe-labeled peptides captured with streptavidin, and analyzed by targeted LC-MS2 Identification Quantitation Explicit determination of peptide Integration of signal from MS2 sequence and probe modification site fragment ions from MS2 spectrum 5 Comprehensive Coverage of Protein and Lipid Kinases Protein kinases Atypical kinases Green: Kinases detected on KiNativ Red: Kinases not detected on KiNativ ~80% of known protein and atypical kinases identified on the platform http://www.kinativ.com/coverage/protein-lipid.html 6 Profiling compound(s) on the KiNativ platform Control sample – add probe Sample: Lysate derived from any cell line or tissue from ANY species Treated sample – add inhibitor followed by probe Inhibited kinase Green: Kinases Blue: Probe Gray: Non-kinases Red: Inhibitor 7 Profiling compound(s) on the KiNativ platform Control sample – add probe MS signalMS Sample: Lysate derived from any cell line or tissue from ANY species Treated sample – add inhibitor
  • 3628-3641-Pruritus in Selected Dermatoses

    3628-3641-Pruritus in Selected Dermatoses

    Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2016; 20: 3628-3641 Pruritus in selected dermatoses K. OLEK-HRAB 1, M. HRAB 2, J. SZYFTER-HARRIS 1, Z. ADAMSKI 1 1Department of Dermatology, University of Medical Sciences, Poznan, Poland 2Department of Urology, University of Medical Sciences, Poznan, Poland Abstract. – Pruritus is a natural defence mech - logical self-defence mechanism similar to other anism of the body and creates the scratch reflex skin sensations, such as touch, pain, vibration, as a defensive reaction to potentially dangerous cold or heat, enabling the protection of the skin environmental factors. Together with pain, pruritus from external factors. Pruritus is a frequent is a type of superficial sensory experience. Pruri - symptom associated with dermatoses and various tus is a symptom often experienced both in 1 healthy subjects and in those who have symptoms systemic diseases . Acute pruritus often develops of a disease. In dermatology, pruritus is a frequent simultaneously with urticarial symptoms or as an symptom associated with a number of dermatoses acute undesirable reaction to drugs. The treat - and is sometimes an auxiliary factor in the diag - ment of this form of pruritus is much easier. nostic process. Apart from histamine, the most The chronic pruritus that often develops in pa - popular pruritus mediators include tryptase, en - tients with cholestasis, kidney diseases or skin dothelins, substance P, bradykinin, prostaglandins diseases (e.g. atopic dermatitis) is often more dif - and acetylcholine. The group of atopic diseases is 2,3 characterized by the presence of very persistent ficult to treat . Persistent rubbing, scratching or pruritus.
  • JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors

    JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors

    Drugs https://doi.org/10.1007/s40265-020-01261-8 CURRENT OPINION JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors Miguel Nogueira1 · Luis Puig2 · Tiago Torres1,3 © Springer Nature Switzerland AG 2020 Abstract Despite advances in the treatment of psoriasis, there is an unmet need for efective and safe oral treatments. The Janus Kinase– Signal Transducer and Activator of Transcription (JAK–STAT) pathway plays a signifcant role in intracellular signalling of cytokines of numerous cellular processes, important in both normal and pathological states of immune-mediated infamma- tory diseases. Particularly in psoriasis, where the interleukin (IL)-23/IL-17 axis is currently considered the crucial pathogenic pathway, blocking the JAK–STAT pathway with small molecules would be expected to be clinically efective. However, relative non-specifcity and low therapeutic index of the available JAK inhibitors have delayed their integration into the therapeutic armamentarium of psoriasis. Current research appears to be focused on Tyrosine kinase 2 (TYK2), the frst described member of the JAK family. Data from the Phase II trial of BMS-986165—a selective TYK2 inhibitor—in psoriasis have been published and clinical results are encouraging, with a large Phase III programme ongoing. Further, the selective TYK2 inhibitor PF-06826647 is being tested in moderate-to-severe psoriasis in a Phase II clinical trial. Brepocitinib, a potent TYK2/JAK1 inhibitor, is also being evaluated, as both oral and topical treatment. Results of studies with TYK2 inhibitors will be important in assessing the clinical efcacy and safety of these drugs and their place in the therapeutic armamentarium of psoriasis.
  • Stem Cell/Wnt

    Stem Cell/Wnt

    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Stem Cell/Wnt Stem cells are required for continuous tissue maintenance within diverse organs, stem cell activity is often externally dictated by the microenvironment (the niche) so that stem cell output is precisely shaped to meet homeostatic needs or regenerative demands. Several key signaling pathways have been shown to play essential roles in this regulatory capacity. Specifically, the JAK/STAT, Hedgehog, Wnt, Notch, Smad, PI3K/phosphatase and tensin homolog, and NK-κB signaling pathways have all been shown experimentally to mediate various stem cell properties, such as self-renewal, cell fate decisions, survival, proliferation, and differentiation. Recent studies mainly focus on cancer stem cell, induced pluripotent stem cell, neural stem cell and maintenance of embryonic stem cell pluripotency. Cancer stem cells (CSCs) have been believed to be responsible for tumor initiation, growth, and recurrence. Numerous agents have been developed to specifically target CSCs by suppressing the expression of pluripotency maintaining factors Nanog, Oct-4, Sox-2, and c-Myc and transcription of GLI. Induced pluripotent stem cells (iPSCs) have the capacity to differentiate into various types of cells, and a self-renewing resource, and scientists can experiment with an unlimited number of pluripotent cells to perfect the process of targeted differentiation, transplantation, and more, for personalized medicine. Novel pathological mechanisms have been elucidated, new drugs originating from iPSC screens are in the pipeline and the first clinical trial using human iPSC-derived products has been initiated. References: [1] Clevers H, et al. Science. 2014 Oct 3;346(6205):1248012. [2] Matsui WH. Medicine (Baltimore).
  • Red, Weeping and Oozing P.51 6

    Red, Weeping and Oozing P.51 6

    DERM CASE Test your knowledge with multiple-choice cases This month–9 cases: 1. Red, Weeping and Oozing p.51 6. A Chronic Condition p.56 2. A Rough Forehead p.52 7. “Why am I losing hair?” p.57 3. A Flat Papule p.53 8. Bothersome Bites p.58 4. Itchy Arms p.54 9. Ring-like Rashes p.59 5. A Patchy Neck p.55 on © buti t ri , h ist oad rig D wnl Case 1 y al n do p ci ca use o er sers nal C m d u rso m rise r pe o utho y fo C d. A cop or bite ngle Red, Weleepirnohig a sind Oozing a se p rint r S ed u nd p o oris w a t f uth , vie o Una lay AN12-year-old boy dpriesspents with a generalized, itchy rash over his body. The rash has been present for two years. Initially, the lesions were red, weeping and oozing. In the past year, the lesions became thickened, dry and scaly. What is your diagnosis? a. Psoriasis b. Pityriasis rosea c. Seborrheic dermatitis d. Atopic dermatitis (eczema) Answer Atopic dermatitis (eczema) (answer d) is a chroni - cally relapsing dermatosis characterized by pruritus, later by a widespread, symmetrical eruption in erythema, vesiculation, papulation, oozing, crust - which the long axes of the rash extend along skin ing, scaling and, in chronic cases, lichenification. tension lines and give rise to a “Christmas tree” Associated findings can include xerosis, hyperlin - appearance. Seborrheic dermatitis is characterized earity of the palms, double skin creases under the by a greasy, scaly, non-itchy, erythematous rash, lower eyelids (Dennie-Morgan folds), keratosis which might be patchy and focal and might spread pilaris and pityriasis alba.
  • Poison Ivy (Toxicodendron Radicans) DESCRIPTION

    Poison Ivy (Toxicodendron Radicans) DESCRIPTION

    Weed Identification and Control Sheet: www.goodoak.com/weeds Poison Ivy (Toxicodendron radicans) DESCRIPTION: Poison ivy is a native woody vine and member of the sumac family. It can be found in shady and sunny sites rambling along the ground, forming a small shrub, or climbing up trees. The vines attach to surfaces by means of thin aerial roots which grow along the length of the stem. The plant always has three leaflets which are often serrated. Usually these leaflets have one dominant lobe, giving the outer two leaves the appearance of mittens with the central leaf resembling a mitten with two thumbs. Young leaves are often dark green or maroonish, and the attractive fall foliage can range from brick to fire- engine red. Poison ivy is generally not considered a threat to native plant communities, in fact, the white berries provide winter food for birds and deer relish the foliage. Though harmless to most animals, many humans are allergic to the urushiol (yoo-roo-shee-ol) oil produced by the plant which results in itching, inflammation and blisters. This oil is found in all parts of the plant during all times of the year. This oil can also be spread by contact with clothing, shoes, pets or equipment that have touched poison ivy weeks or months after initial contact. It can even be transmitted in the air when poison ivy is burned, which presents a severe risk if inhaled and has been known to result in hospitalization and death. Though some people are not alleargic to the oil, its important to wear pants, long sleeves and gloves when working around poison ivy since the allergy can develop af- ter repeated exposures to urushiol.
  • Dermatological Disorders in Tuvalu Between 2009 and 2012

    Dermatological Disorders in Tuvalu Between 2009 and 2012

    MOLECULAR MEDICINE REPORTS 12: 3629-3631, 2015 Dermatological disorders in Tuvalu between 2009 and 2012 LI-JUNG LAN1,2, YING-SHUANG LIEN2,3, SHAO-CHUAN WANG2,4, NESE ITUASO-CONWAY5, MING-CHE TSAI2,6, PAO-YING TSENG6, YU-LIN YEH1, CHUN-TZU CHEN7, KO‑HUANG LUE2,8, JING-GUNG CHUNG9,10 and YU-PING HSIAO1,2 1Department of Dermatology, Chung Shan Medical University Hospital, Taichung 40201; 2Institute of Medicine, School of Medicine, Chung Shan Medical University, Taichung 40201; Departments of 3Obstetrics and Gynecology, and 4Urology, Chung Shan Medical University Hospital, Taichung 40201; 5Public Health, Princess Margaret Hospital, Ministry of Health, Funafuti, Tuvalu; 6International Medical Service Center, Chung Shan Medical University Hospital, Taichung 40201; Departments of 7Chief Secretary Group and 8Pediatrics, Chung Shan Medical University Hospital, Taichung 40201; 9Department of Biological Science and Technology, China Medical University, Taichung 40201; 10Department of Biotechnology, Asia University, Taichung 41354, Taiwan, R.O.C. Received July 1, 2014; Accepted September 18, 2014 DOI: 10.3892/mmr.2015.3806 Abstract. There is a distinct lack of knowledge on the land area of Tuvalu is only 25.9 km2, and the highest point does prevalence of skin disorders in Tuvalu. The aim of the current not exceed 4 m above sea level (1). Currently, an estimated study was to assess the prevalence of cutaneous diseases and 11,000 people live in Tuvalu (1). The Taiwan International to evaluate access dermatological care in Tuvalu. Cutaneous Cooperation and Development Fund (Taiwan ICDF) has disorders in the people of Tuvalu between 2009 and 2012 coordinated the medical resources of Taiwanese hospitals in were examined.
  • Key Potential Drug Launches in 2021

    Key Potential Drug Launches in 2021

    Key Potential Drug Launches in 2021 As a supplement to our well-known quarterly outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2021. These drugs represent new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare. The information in this presentation, including likelihood of approval (LOA) ratings and upcoming catalysts, is up to date as of June 2020. More details about each drug can be viewed instantly on Biomedtracker by clicking the icon. EXTRACT Contents This report covers the following indications: • Allergy • Hematology • Oncology • Psychiatry Atopic Dermatitis (Eczema) Anemia Due to Chronic Renal Failure Biliary Tract Cancer Attention Deficit Hyperactivity Pruritus Hemophilia Bladder Cancer Disorder (ADHD) Bone Marrow & Stem Cell Transplant Major Depressive Disorder • Autoimmune/Immunology (A&I) • Infectious Diseases (ID) Breast Cancer (MDD) Antineutrophil Cytoplasmic Antibodies Clostridium Difficile-Associated- Chronic Lymphocytic Leukemia (CLL) -(ANCA) Associated Vasculitis Diarrhea/Infection (CDAD/CDI) Cutaneous T-Cell Lymphoma (CTCL) • Renal Lupus Nephritis (LN) COVID-19 Diffuse Large B-Cell Lymphoma (DLBCL) Hyperoxaluria Myasthenia Gravis (MG) Pneumococcal Vaccines Follicular Lymphoma (FL) Psoriasis Seasonal Influenza Vaccines Marginal Zone Lymphoma (MZL) • Respiratory Ulcerative Colitis (UC) Melanoma Cystic Fibrosis • Metabolic
  • February 2021 EPS Pipeline Report

    February 2021 EPS Pipeline Report

    Pipeline Report February 2021 Pipeline Report February 2021 © 2021 Envolve. All rights reserved. Page 1 This quarterly at-a-glance publication is developed by our Clinical Pharmacy Drug Information team to increase your understanding of the drug pipeline, Table of Contents ensuring you’re equipped with insights to prepare for shifts in pharmacy benefit management. In this issue, you’ll learn more about key themes and notable drugs referenced in the following points. COVID-19 1 > Veklury is currently the only agent that is FDA-approved for the treatment of COVID-19. Three additional therapeutics and two vaccines have been granted Emergency Use Authorization (EUA), and at least three more vaccines are Recent Specialty Drug Approvals1 4 expected to receive an EUA in the relatively near future. > The previous quarter noted the approval of several breakthrough therapies for rare or ultra-rare conditions, which previously had no available FDA-approved Recent Non-Specialty Drug Approvals 9 treatments — Zokinvy for Hutchinson-Gilford progeria syndrome and progeroid laminopathies, Oxlumo for primary hyperoxaluria type 1, and Imcivree for genetically mediated obesity. Upcoming Specialty Products 10 > Other notable approvals include: Lupkynis — the first oral therapy approved for lupus nephritis; Orladeyo — the first oral therapy approved as prophylaxis of hereditary angioedema attacks;Cabenuva – the first long-acting injectable antiretroviral therapy intended as maintenance treatment of HIV; and Breyanzi — Upcoming Non-Specialty Products 18 the
  • Conference Booklet

    Conference Booklet

    Royal College of Psychiatrists Faculty of General Adult Psychiatry Annual Conference 15-16 October 2020 Conference Booklet Contents Page General information 4 Presentation abstracts and biographies 5 Poster presentations (alphabetically by surname) Quality Improvement 12 Research and Case Reports 51 Education and Training 103 Service Evaluation and Audit 131 Notes 206 General Information Accreditation This conference is eligible for up to 6 CPD hours, subject to peer group approval. Certificates Certificates of attendance will be emailed to delegates after the conference. Feedback A detailed online feedback form can be found by visiting https://www.surveymonkey.co.uk/r/7CCW6ZS All comments received remain confidential and are viewed in an effort to improve future meetings. Social Media If you wish to tweet about the conference use @rcpsychGAP #gapsych2020 Posters Poster viewing is available throughout the conference using the following links Quality Improvement posters Research & case reports posters Education and Training posters Service Evaluation and Audit posters Conference Resources Please see the following link to access the conference resources webpage. 4 Presentation abstracts and biographies (Listed by programme order) Abstracts and biographies not included here were not available at the time of going to print. Thursday 15 October Introduction and Welcome from the Faculty Chair Dr Billy Boland Dr Billy Boland is a Consultant Psychiatrist in community psychiatry and Deputy Medical Director at Hertfordshire Partnership University NHS Foundation Trust. He is the current Chair of the General Adult Faculty at the Royal College of Psychiatrists. Plenary 1: Domestic violence and abuse and mental health during the Covid pandemic and beyond: implications for general adult psychiatrists Professor Louise Howard There has been increasing concern that the Covid pandemic has been associated with an increase in domestic violence and abuse.
  • In Vitro Studies of Poison Oak Immunity. I. in Vitro Reaction of Human Lymphocytes to Urushiol

    In Vitro Studies of Poison Oak Immunity. I. in Vitro Reaction of Human Lymphocytes to Urushiol

    In vitro studies of poison oak immunity. I. In vitro reaction of human lymphocytes to urushiol. V S Byers, … , N Castagnoli, H Baer J Clin Invest. 1979;64(5):1437-1448. https://doi.org/10.1172/JCI109602. Research Article Poison oak, ivy, and sumac dermatitis is a T-cell-mediated reaction against urushiol, the oil found in the leaf of the plants. This hapten is extremely lipophilic and concentrates in cell membranes. A blastogenesis assay employing peripheral blood lymphocytes obtained from humans sensitized to urushiol is described. The reactivity appears 1--3 wk after exposure and persists from 6 wk to 2 mon. The dose-response range is narrow, with inhibition occurring at higher antigen concentrations. Urushiol introduced into the in vitro culture on autologous lymphocytes, erythrocytes and heterologous erythrocytes produces equal results as measured by the optimal urushiol dose, the intensity of reaction, and the frequency of positive reactors. This suggests that the urushiol is passed from introducer to some other presenter cell. Although the blastogenically reactive cell is a T cell, there is also a requirement for an accessory cell, found in the non-T- cell population, for reactivity. Evidence is presented that this cell is a macrophage. Find the latest version: https://jci.me/109602/pdf In Vitro Studies of Poison Oak Immunity I. IN VITRO REACTION OF HUMAN LYMPHOCYTES TO URUSHIOL VERA S. BYERS, WILLIAM L. EPSTEIN, NEAL CASTAGNOLI, and H. BAER, Department of Dermatology and Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California 94143; and Bureau of Biologics, Food and Drug Administration, Bethesda, Maryland 20014 A B S TR A C T Poison oak, ivy, and sumac dermatitis plant represents a severe hazard for outdoor workers is a T-cell-mediated reaction against urushiol, the oil (3,4).
  • Leaves of Three, Let It Be

    Leaves of Three, Let It Be

    Leaves of Three, Let It Be By Doug Coffey, Fairfax Master Gardener Intern My neighbor, an Iranian immigrant, decided to remove a large bush maybe 4 to 5 feet tall and nearly as wide between our properties. I had ignored it, knowing it was so covered in poison ivy that the original plant was unrecognizable. I decided it was better to leave the “bush” alone until I could figure out how to get rid of it. But my neighbor, not consulting with me and not knowing the risks, got out a shovel, dug it up, pulled it out, cut it into pieces and hauled it to the curb. Within Brandeia University hours, he was in the emergency room and then several days after in the hospital getting massive doses of photo: steroids. He was so uncomfortable with the extensive blistering, rash and itching that he couldn’t even find a way to sleep. Even thinking about it today makes my skin itch. !P!o!i!s!o!n! !i!v!y! !(!T!o!x!i!c!o!d!e!n!d!r!o!n! !r!a!d!i!c!a!n!s!)! !c!o!n!t!a!i!n!s! !a! !l!a!c!q!u!e!r!-!t!y!p!e! !o!i!l! !c!a!ll! !e!d! !u!r!u!s!h!i!o!l!,! !(!y!o!u!-!R!o!o!-!s!h!e!e!-!a!l!l!)! !t!h!a!t! !c!a!n! !c!a!u!s!e! !r!e!d!n!e!s!s!,! !s!w!e!l!l!i!n!g! !a!n!d! !b!l!i!s!t!e!r!s!.! ! !U!r!u!s!h!i!o!l! !i!s! !f!o!u!n!d! !i!n! !a!l!l! !p!a!r!t!s! !o!f! !t!h!e! !p!l!a!n!t! --! !t!h!e! !l!e!a!v!e!s!,! !s!t!e!m!s! !a!n!d! !e!v!e!n! !t!h!e! !r!o!o!t!s!,! !a!n!d! !i!s! !p!a!r!t! !o!f! !t!h!e! !p!l!a!n!t’!s! !d!e!f!e!n!s!e! !a!g!a!i!n!s!t! !b!r!o!w!s!i!n!g! !a!n!i!m!a!l!s! !a!n!d! !h!u!m!a!n! !b!e!i!n!g!s! !w!h!o! !t!r!y! !t!o! !r!e!m!o!v!e! !i!t!.! !T!h!e! !o!i!l! !i!s! !m!o!s!t!l!y!